A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Public ClinicalTrials.gov record NCT05248867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study was to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in participants with moderate to severe GL. This was a 12-week study in which eligible subjects were enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants were randomly assigned to receive AGN-151586 or placebo. There was 1 in a 4 chance that participants would receive placebo. Around 600 adult participants with moderate to severe GL were to be enrolled in the study in approximately 38 sites across the world. Participants received either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may have received an open-label treatment of AGN-151586 during the study. Participants attended regular visits during the study at a study site. The effect of the treatment was checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
Study identification
- NCT ID
- NCT05248867
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 638 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2022 (Actual)
- Primary completion
- Mar 17, 2023 (Actual)
- Completion
- Mar 17, 2023 (Actual)
- Last update posted
- May 24, 2024
2022 – 2023
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Total Skin and Beauty Derm Ctr /ID# 232378 | Birmingham | Alabama | 35205 | — |
| Clinical Testing of Beverly Hills /ID# 233195 | Encino | California | 91436-2124 | — |
| Westside Aesthetics /ID# 232443 | Los Angeles | California | 90025-1708 | — |
| The Research Center at The Maas Clinic /ID# 241262 | San Francisco | California | 94115-1809 | — |
| Center for Dermatology and Dermatologic Surgery /ID# 232315 | Washington D.C. | District of Columbia | 20037-1445 | — |
| Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232439 | Boca Raton | Florida | 33431-6465 | — |
| Dermatology Clinic & Cosmetic Center /ID# 244295 | Baton Rouge | Louisiana | 70808-4691 | — |
| Delricht Research /ID# 241253 | New Orleans | Louisiana | 70115 | — |
| Skincare Physicians /ID# 233938 | Chestnut Hill | Massachusetts | 02467 | — |
| BOYD Beauty Birmingham /ID# 232383 | Birmingham | Michigan | 48009-6301 | — |
| Skin Search of Rochester Inc. /ID# 232549 | Rochester | New York | 14623 | — |
| Aesthetic Solutions /ID# 232389 | Chapel Hill | North Carolina | 27517-9901 | — |
| Aventiv Research Dublin /ID# 233936 | Dublin | Ohio | 43016 | — |
| KGL Skin Study Center, LLC /ID# 233549 | Newtown Square | Pennsylvania | 19073-2228 | — |
| Nashville Center for Laser and Facial Surgery /ID# 242535 | Nashville | Tennessee | 37203-1513 | — |
| Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 232410 | Austin | Texas | 78746-4720 | — |
| Dallas Plastic Surgery Institute /ID# 232328 | Dallas | Texas | 75231 | — |
| Austin Institute for Clinical Research at SBA Dermatology /ID# 232316 | Houston | Texas | 77056-4129 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05248867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2024 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05248867 live on ClinicalTrials.gov.